Found: 102
Select item for more details and to access through your institution.
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1005, doi. 10.1002/ajh.26595
- By:
- Publication type:
- Article
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E201, doi. 10.1002/ajh.26526
- By:
- Publication type:
- Article
Non‐coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E100, doi. 10.1002/ajh.26457
- By:
- Publication type:
- Article
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. 241, doi. 10.1002/ajh.26047
- By:
- Publication type:
- Article
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 6, p. E114, doi. 10.1002/ajh.24720
- By:
- Publication type:
- Article
PET-positive lymphadenopathy in CLL-Not always Richter transformation.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 4, p. 405, doi. 10.1002/ajh.24566
- By:
- Publication type:
- Article
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 11, p. 1065, doi. 10.1002/ajh.24140
- By:
- Publication type:
- Article
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.668162
- By:
- Publication type:
- Article
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
- Published in:
- Drugs, 2019, v. 79, n. 12, p. 1287, doi. 10.1007/s40265-019-01163-4
- By:
- Publication type:
- Article
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
- Published in:
- Acta Haematologica, 2018, v. 140, n. 1, p. 30, doi. 10.1159/000490092
- By:
- Publication type:
- Article
1719. Incidence and Characterization of Invasive Fungal Infections (IFIs) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (IBR).
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S630, doi. 10.1093/ofid/ofz360.1582
- By:
- Publication type:
- Article
2211. Impact of Early Fiberoptic Bronchoscopy on Microbiological Diagnostic Rate and Clinical Outcomes of Pneumonia in Acute Leukemia Patients.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S753, doi. 10.1093/ofid/ofz360.1889
- By:
- Publication type:
- Article
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 8, p. 610, doi. 10.1016/j.clml.2023.04.006
- By:
- Publication type:
- Article
CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S315, doi. 10.1016/S2152-2650(21)01746-8
- By:
- Publication type:
- Article
Poster: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01392-6
- By:
- Publication type:
- Article
Oral Abstract: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01273-8
- By:
- Publication type:
- Article
Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S283, doi. 10.1016/j.clml.2019.07.221
- By:
- Publication type:
- Article
KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes in Patients Who Were Treated with Prior Blinatumomab in ZUMA-3.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S184, doi. 10.1016/j.clml.2018.07.015
- By:
- Publication type:
- Article
Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S12, doi. 10.1016/j.clml.2017.09.040
- By:
- Publication type:
- Article
Managing BTK Inhibitor-Refractory CLL.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S194, doi. 10.1016/j.clml.2017.08.088
- By:
- Publication type:
- Article
Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S304, doi. 10.1016/j.clml.2017.07.100
- By:
- Publication type:
- Article
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 5, p. 568, doi. 10.1016/j.clml.2013.03.012
- By:
- Publication type:
- Article
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2023, v. 482, n. 6, p. 1011, doi. 10.1007/s00428-023-03520-x
- By:
- Publication type:
- Article
Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 5, p. 1, doi. 10.1038/s41408-022-00675-9
- By:
- Publication type:
- Article
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 3, p. 1, doi. 10.1038/s41408-021-00436-0
- By:
- Publication type:
- Article
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01379-0
- By:
- Publication type:
- Article
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
- Published in:
- British Journal of Haematology, 2010, v. 148, n. 3, p. 386, doi. 10.1111/j.1365-2141.2009.07965.x
- By:
- Publication type:
- Article
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
- Published in:
- British Journal of Haematology, 2008, v. 141, n. 1, p. 36, doi. 10.1111/j.1365-2141.2008.07012.x
- By:
- Publication type:
- Article
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors.
- Published in:
- British Journal of Haematology, 2007, v. 136, n. 6, p. 800, doi. 10.1111/j.1365-2141.2007.06513.x
- By:
- Publication type:
- Article
Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray.
- Published in:
- British Journal of Haematology, 2006, v. 135, n. 2, p. 184, doi. 10.1111/j.1365-2141.2006.06266.x
- By:
- Publication type:
- Article
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2003, v. 120, n. 3, p. 452, doi. 10.1046/j.1365-2141.2003.04118.x
- By:
- Publication type:
- Article
A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies.
- Published in:
- EJHaem, 2022, v. 3, n. 2, p. 492, doi. 10.1002/jha2.427
- By:
- Publication type:
- Article
The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.
- Published in:
- Journal of Experimental Pharmacology, 2021, v. 13, p. 923, doi. 10.2147/JEP.S265284
- By:
- Publication type:
- Article
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
- Published in:
- European Journal of Haematology, 2008, v. 80, n. 4, p. 296, doi. 10.1111/j.1600-0609.2007.01023.x
- By:
- Publication type:
- Article
The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells.
- Published in:
- PLoS ONE, 2013, v. 8, n. 12, p. 1, doi. 10.1371/journal.pone.0083830
- By:
- Publication type:
- Article
Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC.
- Published in:
- PLoS ONE, 2012, v. 7, n. 12, p. 1, doi. 10.1371/journal.pone.0051390
- By:
- Publication type:
- Article
A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia.
- Published in:
- PLoS ONE, 2011, v. 6, n. 12, p. 1, doi. 10.1371/journal.pone.0028277
- By:
- Publication type:
- Article
Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 14, p. 2192, doi. 10.1002/cncr.34787
- By:
- Publication type:
- Article
The cure of leukemia through the optimist's prism.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 2, p. 240, doi. 10.1002/cncr.33933
- By:
- Publication type:
- Article
Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2648, doi. 10.1002/cncr.33529
- By:
- Publication type:
- Article
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 61, doi. 10.1111/bjh.17498
- By:
- Publication type:
- Article
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 1, p. e1, doi. 10.1111/bjh.16117
- By:
- Publication type:
- Article
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 1, p. 184, doi. 10.1111/bjh.15791
- By:
- Publication type:
- Article
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 961, doi. 10.1111/bjh.15666
- By:
- Publication type:
- Article
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 4, p. 504, doi. 10.1111/bjh.15421
- By:
- Publication type:
- Article
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 3, p. 442, doi. 10.1111/bjh.14806
- By:
- Publication type:
- Article
Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 4, p. 597, doi. 10.1111/bjh.14398
- By:
- Publication type:
- Article
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 33, doi. 10.1111/bjh.15018
- By:
- Publication type:
- Article
Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 2, p. 266, doi. 10.1111/bjh.14859
- By:
- Publication type:
- Article